Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01955109 · ClinicalTrials.gov registry record · Phase 2
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
A Phase 2 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT01955109 is a Phase 2 study that has completed, run by DBV Technologies. The registered enrollment target is 171 participants.
The verdict
NCT01955109, a Phase 2 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: * To assess the efficacy of Viaskin Peanut after up to 36 months of treatment. * To evaluate the safety of long-term treatment with Viaskin Peanut. * To evaluate sustained unresponsiveness to peanut after a period of 2 months without treatment in subjects showing desensitization to peanut after treatment with Viaskin Peanut.
Interventions
- BIOLOGICAL Viaskin Peanut 250 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01955109
The ClinicalTrials.gov registry entry for NCT01955109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Viaskin Peanut 250 mcg is the first listed.
NCT01955109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01955109 about?
NCT01955109 is a clinical study titled "Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children". The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: * To assess the efficacy of Viaskin Peanut after up to 36 months of treatment. * To evaluate the safety of long-term treatment w...
What is the current status of trial NCT01955109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2013-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01955109?
The interventions under investigation include: Viaskin Peanut 250 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01955109?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.